HZNP — Horizon Therapeutics Share Price
Last trade - 00:00- $26.63bn
- $26.72bn
- $3.63bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 16.57 | ||
| PEG Ratio (f) | 0.52 | ||
| EPS Growth (f) | 46.41% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.5 | ||
| Price to Tang. Book | 32.83 | ||
| Price to Free Cashflow | 21.76 | ||
| Price to Sales | 6.42 | ||
| EV to EBITDA | 27.31 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.66% | ||
| Return on Equity | 7.5% | ||
| Operating Margin | 12.84% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,207.57 | 1,300.03 | 2,200.43 | 3,226.41 | 3,629.04 | 3,771.03 | 4,309.8 | 28% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -26.31 | +24.59 | -1.68 | +80.86 | +31.88 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Horizon Therapeutics plc is an Ireland-based global biotechnology company. The Company is focused on the discovery, development and commercialization of medicines that address the critical needs of people impacted by rare, autoimmune and severe inflammatory diseases. The Company’s portfolio of medicines include ACTIMMUNE, BUPHENYL (sodium phenylbutyrate), KRYSTEXXA pegloticase, PROCYSBI (cysteamine bitartrate), Prescription RAVICTI (glycerol phenylbutyrate), TEPEZZA teprotumumab-trbw and other. ACTIMMUNE is part of a drug regimen used to treat Chronic Granulomatous Disease (CGD). BUPHENYL (sodium phenylbutyrate) is a tablet for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contains sodium phenylbutyrate. PROCYSBI (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a prescription medicine used to treat nephropathic cystinosis in adults and children 1 year of age and older.
Directors
- Timothy Walbert CHM (54)
- Paul Hoelscher CFO (56)
- Irina Konstantinovsky CHO (51)
- Aaron Cox EVF (39)
- Barry Moze EVP (67)
- Brian Beeler EVP (48)
- Daniel Camardo EVP (53)
- Geoffrey Curtis EVP (46)
- Michael DesJardin EVP (63)
- Vikram Karnani EVP (46)
- Jeffrey Kent EVP (59)
- Andy Pasternak EVP (50)
- Jeffrey Sherman EVP (66)
- Elizabeth Thompson EVP
- Michael Grey LED (68)
- William Daniel IND (69)
- Jeffrey Himawan IND (56)
- Susan Mahony IND (56)
- Gino Santini IND (65)
- James Shannon IND (64)
- H. Thomas Watkins IND (68)
- Pascale Witz IND (54)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- December 20th, 2011
- Public Since
- August 11th, 2010
- No. of Shareholders
- 25
- No. of Employees
- 2,145
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 228,925,986
- Address
- Connaught House, DUBLIN, D04 C5Y6
- Web
- https://www.horizontherapeutics.com/
- Phone
- +353 17722100
- Contact
- Tina Ventura
- Auditors
- PricewaterhouseCoopers LLP
Latest News for HZNP
Upcoming Events for HZNP
Horizon Therapeutics PLC Annual Shareholders Meeting
Q2 2023 Horizon Therapeutics PLC Earnings Release
Similar to HZNP
Abcam
NASDAQ Global Select Market
Acelyrin
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 07:11 UTC, shares in Horizon Therapeutics are trading at $100.23. This share price information is delayed by 15 minutes.
Shares in Horizon Therapeutics last closed at $100.23 and the price had moved by +21.96% over the past 365 days. In terms of relative price strength the Horizon Therapeutics share price has outperformed the S&P500 Index by +4.7% over the past year.
The overall consensus recommendation for Horizon Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Horizon Therapeutics does not currently pay a dividend.
Horizon Therapeutics does not currently pay a dividend.
Horizon Therapeutics does not currently pay a dividend.
To buy shares in Horizon Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $100.23, shares in Horizon Therapeutics had a market capitalisation of $22.87bn.
Here are the trading details for Horizon Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: HZNP
Based on an overall assessment of its quality, value and momentum Horizon Therapeutics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Horizon Therapeutics is $116.86. That is 16.59% above the last closing price of $100.23.
Analysts covering Horizon Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of $5.12 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Horizon Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -19.71%.
As of the last closing price of $100.23, shares in Horizon Therapeutics were trading -0.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Horizon Therapeutics PE ratio based on its reported earnings over the past 12 months is 16.57. The shares last closed at $100.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Horizon Therapeutics' management team is headed by:
- Timothy Walbert - CHM
- Paul Hoelscher - CFO
- Irina Konstantinovsky - CHO
- Aaron Cox - EVF
- Barry Moze - EVP
- Brian Beeler - EVP
- Daniel Camardo - EVP
- Geoffrey Curtis - EVP
- Michael DesJardin - EVP
- Vikram Karnani - EVP
- Jeffrey Kent - EVP
- Andy Pasternak - EVP
- Jeffrey Sherman - EVP
- Elizabeth Thompson - EVP
- Michael Grey - LED
- William Daniel - IND
- Jeffrey Himawan - IND
- Susan Mahony - IND
- Gino Santini - IND
- James Shannon - IND
- H. Thomas Watkins - IND
- Pascale Witz - IND